Printer Friendly Version

PHARMACY PRODUCT ALERT



Now available!



» New 400 mg tablets


» Convenience of just 1 tablet twice a day®


» New dose packs to promote full-course compliance

- » 10-day dose pack for acute bacterial exacerbation of chronic bronchitis (ABECB)
- » 14-day dose pack for community-acquired pneumonia (CAP)

» New co-pay assistance program ensures affordability

- » Provide branded prescription Spectracef® 400 mg at a Tier 1 price*
- » Help ensure patients receive their prescribed medication





» Use this ordering information to give patients the broad-spectrum potency and first-course reliability of Spectracef® 400 mg tablets.

Product Description (NDC)	Bergen	Belco	Cardinal	Dakota Drug	HD Smith	Harvard Drug Group	Kinray
Spectracef® 400 mg 20-ct box (10122-802-20)	973255	293704	4123774	683532	2080220	890009	322636
Spectracef® 400 mg 28-ct box (10122-802-28)	973248	293712	4123782	683458	2080228	890011	323485

Product Description (NDC)	McKesson Drug	Miami Luken	Morris Dickson	NC Mutual	Prescription Supply	Rochester Drug	Smith Drug
Spectracef® 400 mg 20-ct box (10122-802-20)	1718931	093856	930008	696005	548834	10195634	237305
Spectracef® 400 mg 28-ct box (10122-802-28)	1718956	093864	930065	636013	548842	10195626	257378

New Spectracef® 400 mg tablets—the value of 1-course reliability

- » Powerful third-generation cephalosporin activity
- » Dependable coverage against gram-positive and gram-negative bacteria1
- » Reliable cure rates and low incidence of resistance
- » Proven tolerability and safety¹

Please see Important Safety Information below.

Click here to view **full Prescribing Information**.

For additional information, visit www.spectracef.com

Important Safety Information:

INDICATIONS AND USAGE

SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below.

Acute Bacterial Exacerbation of Chronic Bronchitis caused by *Haemophilus influenzae* (including ?-lactamase-producing strains), *Haemophilus parainfluenzae* (including ?-lactamase producing strains), *Streptococcus pneumoniae* (penicillin susceptible strains only), or *Moraxella catarrhalis* (including ?-lactamase-producing strains).

Community-Acquired Pneumonia caused by *Haemophilus influenzae* (including ?-lactamase-producing strains), *Haemophilus parainfluenzae* (including ?-lactamase-producing strains), *Streptococcus pneumoniae* (penicillin-susceptible strains only), or *Moraxella catarrhalis* (including ?-lactamase producing strains).

Pharyngitis/Tonsillitis caused by *Streptococcus pyogenes*. NOTE: SPECTRACEF® is effective in the eradication of *Streptococcus pyogenes* from the oropharynx. SPECTRACEF® has not been studied for

the prevention of rheumatic fever following *Streptococcus pyogenes* pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever.

Uncomplicated Skin and Skin-Structure Infections caused by *Staphylococcus aureus* (including ?-lactamase-producing strains) or *Streptococcus pyogenes*.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Please see full Prescribing Information for Spectracef® contraindications and warnings.

*For eligible patients with commercial third-party payor plans. Terms and conditions apply.

Reference: 1. Spectracef® [package insert]. Cornerstone BioPharma, Inc.; Cary, NC: 2007.





SPECTRACEF® is a registered trademark of Meiji Seika Kaisha, LTD, for antibiotic pharmaceutical preparations. © 2008 Cornerstone Therapeutics Inc. All rights reserved. December 2008. CTS868A1108



Please <u>remove my email</u> from your list.